Kenton D. Leatherman Spine Center, 210 East Gray Street, Suite 900, Louisville, KY 40202, USA.
Spine J. 2009 Nov;9(11):880-5. doi: 10.1016/j.spinee.2009.03.013. Epub 2009 May 17.
Reported fusion rates for spine fusions using iliac crest bone graft (ICBG) vary between 40% and 100% because of different fusion techniques, patient comorbidity, diagnosis and assessment criteria.
We report two-year results of single-level instrumented posterolateral fusions evaluated with radiographs, fine-cut computed tomography (CT) scans with reconstructions and outcome measures. STUDY DESIGN/ SETTING: Retrospective analysis of data from a prospective multicenter randomized clinical controlled trial.
Patients with various degenerative diagnoses enrolled in the control arm of a Food and Drug Administration (FDA)-regulated, multicenter trial of single-level decompression and posterolateral fusion for degenerative lumbar disease.
Short Form-36 (SF-36), Oswestry Disability Index (ODI), Numeric Rating Scales (0-20) for back, leg, and graft site pain, CT scans, anteroposterior and lateral flexion/extension radiographs.
Patients enrolled in an FDA-regulated, multicenter trial at 29 sites with degenerative lumbar disease treated with single-level instrumented posterolateral fusion with ICBG were included in the analysis. Demographic and surgical data were collected. Clinical outcomes were followed using standard metrics. Fusion was assessed by independent radiologists at 6, 12, and 24 months postoperatively. Two fusion criteria were compared: anteroposterior and flexion/extension radiographs to assess motion and bridging bone, with CT scans as needed to confirm bridging bone; and CT scan assessment for bridging bone only.
One hundred ninety-four of 224 subjects (86.6%) completed the study. The mean operative time was 2.9 hours with a blood loss of 448.6 mL. The average graft volume was 36.3 mL. There were 21 (9.4%) wound infections, 18 (8.0%) incidental durotomies, 3 (1.3%) implant displacements, 2 (0.9%) malpositioned implants, and 17 (7.6%) graft-related complications. Twenty-seven patients (13.9%) required reoperation, the majority for nonunions. Fusion rates based on radiographs with selective CTs at 6, 12, and 24 months were 65.3%, 82.5%, and 89.3%, respectively. Fusion rates based on bridging bone on CT scans were 56.1%, 71.5%, 83.9%, respectively. Two-year improvement for all outcome measures was significant (p<.001)-ODI 25.3, SF-36 Physical Component Score (PCS) 12.2, back pain 7.9, and leg pain 7.1. Two years postoperatively, 60% of patients complained of graft site pain (mean pain score=8.5).
In a large series of patients who had primary single-level instrumented posterolateral fusion with ICBG, evidence of bridging bone on fine-cut CT scans improved with time to 83.9% at 24 months. Significant improvement from baseline was noted in all clinical outcome measures at all time intervals with 75% achieving minimum clinically important difference (MCID) for ODI and 66% achieving MCID for SF-36 PCS.
由于不同的融合技术、患者合并症、诊断和评估标准,使用髂嵴骨移植物(ICBG)进行脊柱融合的报告融合率在 40%到 100%之间变化。
我们报告了使用影像学、精细 CT 扫描(CT)和重建以及结果测量评估的单节段后路融合的两年结果。
研究设计/设置:对食品和药物管理局(FDA)监管的、多中心、单节段减压和后路融合退行性腰椎疾病的前瞻性多中心随机对照临床试验数据的回顾性分析。
各种退行性诊断的患者,参加退行性腰椎疾病多中心试验的对照组,接受单节段减压和后路融合。
简明健康调查问卷 36 项(SF-36)、Oswestry 残疾指数(ODI)、背部、腿部和移植物部位疼痛的数字评分量表(0-20)、CT 扫描、前后和侧屈/伸展位 X 线片。
在 29 个地点参加 FDA 监管的多中心试验的退行性腰椎疾病患者,接受单节段后路融合,使用 ICBG 进行治疗,符合纳入分析的条件。收集人口统计学和手术数据。使用标准指标对临床结果进行随访。术后 6、12 和 24 个月,由独立放射科医生评估融合。比较了两种融合标准:前后位和屈伸位 X 线片评估运动和桥接骨,需要时进行 CT 扫描以确认桥接骨;以及仅使用 CT 扫描评估桥接骨。
224 名患者中有 194 名(86.6%)完成了研究。平均手术时间为 2.9 小时,失血量为 448.6 毫升。平均移植物体积为 36.3 毫升。有 21 例(9.4%)发生伤口感染,18 例(8.0%)发生意外硬脑膜切开术,3 例(1.3%)发生植入物移位,2 例(0.9%)发生植入物错位,17 例(7.6%)发生移植物相关并发症。27 例(13.9%)患者需要再次手术,大多数是为了治疗不愈合。根据 6、12 和 24 个月时的 X 线片和选择性 CT 融合率分别为 65.3%、82.5%和 89.3%。根据 CT 扫描上的桥接骨,融合率分别为 56.1%、71.5%和 83.9%。所有结局测量的两年改善均具有统计学意义(p<0.001)-ODI 25.3,SF-36 生理成分评分(PCS)12.2,腰背疼痛 7.9,腿部疼痛 7.1。术后两年,60%的患者抱怨移植物部位疼痛(平均疼痛评分=8.5)。
在接受单节段后路融合和 ICBG 治疗的大量患者中,精细 CT 扫描上桥接骨的证据随着时间的推移而改善,24 个月时达到 83.9%。所有临床结局指标在所有时间间隔均有显著改善,所有指标均从基线水平改善,75%的患者 ODI 达到最小临床重要差异(MCID),66%的患者 SF-36 PCS 达到 MCID。